CURRICULUM FORMATIVO E PROFESSIONALE

Dr. JOSUEL ORA

INFORMAZIONI PERSONALI

Nome e Cognome: Dr. Josuel Ora
Data di nascita: ***
Luogo di nascita: ***
Indirizzo: ***
Telefono: ***
E-mail: josuel.ora@uniroma2.it
Nazionalità: Italiana

Posizione attuale: Ricercatore (RTT) settore disciplinare 06/MEDS 07 Malattie dell'apparato Respiratorio presso l'Università degli studi di Roma Tor Vergata

---

ESPERIENZA PROFESSIONALE

Incarichi Accademici e Didattici

2025 – presente

- **Università "Unicamillus", Roma**
  - Ricercatore (RTT) settore disciplinare 06/MEDS 07 Malattie dell'apparato Respiratorio, Dipartimante di Medicina Sperimentale presso l'Università degli Studi di Roma Tor Vergata

2024 – presente

- **Università "Unicamillus", Roma**
  - Professore a contratto di Malattie Respiratorie per:
    - Corso di Laurea in Medicina e Chirurgia in lingua Inglese (Malattie dell'apparato respiratorio) (Facoltà di Medicina e Chirurgia)

2020 – Presente

- **Università "Tor Vergata" di Roma**
  - Coordinatore Didattico del Master di I livello in Tecniche di Fisiopatologia Respiratoria
  - Tutor per i moduli: "Tecniche di Fisiopatologia Respiratoria (base e avanzato)" e "Test da sforzo Cardiopolmonare, Analisi dei gas ematici – scambio gassoso"

2020 – 2024

- **Università Cattolica "Nostra Signora del Buon Consiglio", Tirana (Albania)**
  - Professore a contratto di Malattie Respiratorie per:

  - Corso di Laurea in Fisioterapia (Facoltà di Medicina e Chirurgia) [dal 2018]
  - Master in Scienze della Riabilitazione delle Professioni Sanitarie (Facoltà di Medicina e Chirurgia) [dal 2020]

2016 – Presente

- **Università "Tor Vergata" di Roma**
  - Docente esperto in "Malattie Polmonari" (Corso di Laurea in Medicina e Chirurgia – corso in italiano)
  - Professore a contratto di "Malattie Polmonari – pratica clinica III" (Corso di Laurea in Medicina e Chirurgia – corso in inglese)
  - Tutor presso la Scuola di Specializzazione in Malattie del Sistema Respiratorio

2015 – 2019

- **Università "Tor Vergata" di Roma**
  - Professore a contratto (Malattie del Sistema Respiratorio, Scuola di Specializzazione in Malattie del Sistema Respiratorio)

Altre esperienze di insegnamento, corsi e congressi

- Relatore a Congressi Nazionali e Regionali AIPO (Associazione Italiana di Pneumologia Ospedaliera) dal 2009
- Attività di docenza per la Scuola Medica Ospedaliera (SMO) su diverse tematiche specialistiche (2014–2017)
- Letture per la Società Italiana di Pneumologia dello Sport (SIPS), European Respiratory Society (ERS) e Società Italiana di Endoscopia Toracica (SIET)

Altri incarichi

- **2024 – Presente**: Editor Associato, *SciBase Clinical and Medical Case Reports*
- **2022 – Presente**:
  - Curatore della rubrica *LUNG UPDATE* per AIPONET
  - Editor Associato per *Frontiers in Drug Safety and Regulation*
- **2020 – Presente**:
  - Editor Associato per *BMC Pulmonary Medicine*
  - Editor Associato per *Rassegna di Patologia dell'Apparato Respiratorio*

ISTRUZIONE E FORMAZIONE

- **Laurea in Medicina e Chirurgia**
  Università di Roma "La Sapienza" – 07/07/2003 – Voto: 110/110 e lode
- **Specializzazione in Medicina Interna**
  Università di Roma "La Sapienza" – 20/11/2008 – Voto: 70/70 e lode
- **Dottorato di Ricerca in Medicina Sperimentale e dei Sistemi (ex Fisiopatologia)**
  Università degli Studi di Roma "Tor Vergata" – 29/05/2024
- **Post Doctoral Fellow (2007-2009)**
  Università Queen's, Kingston (Canada) – Unità di Ricerca Respiratoria (Prof. Denis E. O'Donnell)

- **Master di II livello in Gestione Sanitaria (Management sanitario) – 2019**
  Università "Niccolò Cusano" di Roma
- **Abilitazioni Scientifiche Nazionali**
  - 2021: Professore Associato (Livello II) – 06/D1 (SSD MED/10) e 06/B1 (SSD MED/09)
  - 2023: Professore Ordinario (Livello I) – 06/D1 (SSD MED/10)
- **Iscrizione Albo dei Medici**
  - Albo provinciale di Roma, n. 52902, dal 09/12/2003
- **Lingue**
  - Italiano (madrelingua)
  - Inglese (livello C1 – Certificate of Advanced English, Cambridge ESOL)

COMPETENZE PERSONALI

- **Competenze comunicative**
  - Pluriennale attività di docenza universitaria e di relatore a congressi nazionali e internazionali
  - Collaborazione con associazioni scientifiche (AIPO, ERS, SIET, SIPS)
- **Competenze organizzative/gestionali**
  - Coordinatore Didattico del Master di I livello in Tecniche di Fisiopatologia Respiratoria
  - Membro esterno in commissioni di valutazione tesi di Dottorato o di Ricerca
- **Competenze professionali**
  - Profonda esperienza nella gestione di Malattie dell'Apparato Respiratorio (BPCO, Asma, Insufficienza Respiratoria)
  - Eccellente conoscenza di fisiopatologia respiratoria (test da sforzo cardiopolmonare, meccanica respiratoria, dispnea)
  - Ruolo di Investigatore principale o co-investigatore in numerosi studi clinici nazionali e internazionali
- **Competenze digitali**
  - Uso avanzato di strumenti informatici (pacchetto Office, software di analisi statistica)
  - Esperienza con piattaforme di e-learning e telemedicina

ATTIVITÀ DI RICERCA E PROGETTI

- **Linee di ricerca principali**
  - Test da sforzo cardiopolmonare, meccanica respiratoria, funzionalità polmonare (BPCO, asma, obesità, post SARS-CoV-2)
  - Studio dei meccanismi della dispnea e impatto di farmaci broncodilatatori
  - Terapie innovative (LAMA/LABA/ICS, biotecnologici) in asma e BPCO
- **Collaborazioni**
  - Team di ricerca nazionali e internazionali (Italia, Canada, Albania).
  - Co-autore di numerose pubblicazioni su riviste peer-reviewed.

PUBBLICAZIONI E RISULTATI SCIENTIFICI

- **ORCID**: https://orcid.org/0000-0001-9877-7851

Elenco di tutte le pubblicazioni e documenti disponibili su scopus

1. Phillips DB, James MD, Vincent SG, Elbehairy AF, Neder JA, Kirby M, et al. Physiological Characterization of Preserved Ratio Impaired Spirometry in the CanCOLD Study: Implications for Exertional Dyspnea and Exercise Intolerance. American journal of respiratory and critical care medicine [Internet]. 2024;209(11):1314–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85194916717&doi=10.1164%2frccm.202307-1184OC&partnerID=40&md5=f054f899a9d58f421fbe70e371df497f
2. **Ora J,** Giorgino FM, Bettin FR, Gabriele M, Rogliani P. Pulmonary Function Tests: Easy Interpretation in Three Steps. JCM [Internet]. 2024 Jun 22 [cited 2024 Jun 29];13(13):3655. Available from: https://www.mdpi.com/2077-0383/13/13/3655 (scopus non available)
3. **Ora J**, Rogliani P. Clinical challenges in applying the new lung function test interpretive strategies: navigating pitfalls and possible solutions. European Respiratory Journal [Internet]. 2024;63(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183589827&doi=10.1183%2f13993003.01439-2023&partnerID=40&md5=fd19a76d415d1f082c969ceb854d4b27
4. **Ora J**, De Marco P, Gabriele M, Cazzola M, Rogliani P. Exercise-Induced Asthma: Managing Respiratory Issues in Athletes. Journal of Functional Morphology and Kinesiology [Internet]. 2024;9(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85188902623&doi=10.3390%2fjfmk9010015&partnerID=40&md5=fc1a522ef29dbe9a07fce7529cd3118b
5. Matera MG, **Ora J**, Calzetta L, Rogliani P, Cazzola M. Biologics for asthma and risk of pneumonia. Journal of Asthma [Internet]. 2024; Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85184456901&doi=10.1080%2f02770903.2024.2311236&partnerID=40&md5=d1121c9e1027db8638acc1d2031f4344
6. Salton F, Confalonieri P, Centanni S, Mondoni M, Petrosillo N, Bonfanti P, et al. Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS). European Respiratory Journal [Internet]. 2023;61(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148936444&doi=10.1183%2f13993003.01514-2022&partnerID=40&md5=f1ed057dd4dff95b09370b64cb01de61
7. Rogliani P, Radovanovic D, **Ora J,** Starc N, Verri S, Pistocchini E, et al. Assessing the relationship between cardiovascular and small airway disease and acute events in COPD: The ARCADIA study protocol. Pulmonary Pharmacology and Therapeutics [Internet]. 2023;82. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85165699199&doi=10.1016%2fj.pupt.2023.102231&partnerID=40&md5=b8c329383ab6146050de8aef9febc10d
8. Rogliani P, Laitano R, **Ora J,** Beasley R, Calzetta L. Strength of association between comorbidities and asthma: a meta-analysis. European Respiratory Review [Internet]. 2023;32(167). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149643647&doi=10.1183%2f16000617.0202-2022&partnerID=40&md5=7a310fa700f29ac2f0912d6e59975900
9. **Ora J**, Rogliani P, Ferron F, Vignuoli M, Valentino L, Pontoni G, et al. Effects of SARS-CoV-2 on Pulmonary Function and Muscle Strength Testing in Military Subjects According to the Period of Infection: Cross-Sectional Study. Diagnostics [Internet]. 2023;13(10). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160524810&doi=10.3390%2fdiagnostics13101679&partnerID=40&md5=9988a6e01e098360e90c6a9bd89596de
10. **Ora J**, Calzetta L, Frugoni C, Puxeddu E, Rogliani P. Expert guidance on the management and challenges of long-COVID syndrome: a systematic review. Expert Opinion on Pharmacotherapy

[Internet]. 2023;24(3):315–30. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145474199&doi=10.1080%2f14656566.2022.2161365&partnerID=40&md5=14e8cafde62fa2fa605c8822487fb34b

11. Matera MG, Rogliani P, **Ora J**, Calzetta L, Cazzola M. A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome. Expert Opinion on Investigational Drugs [Internet]. 2023;32(9):793–802. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85172158146&doi=10.1080%2f13543784.2023.2263366&partnerID=40&md5=588c24c39c311c03a48fa3da8caf92ba
12. Matera MG, **Ora J**, Rogliani P, Cazzola M. An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. Expert Opinion on Drug Discovery [Internet]. 2023;18(9):951–63. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85164187610&doi=10.1080%2f17460441.2023.2230885&partnerID=40&md5=ec2bcbc7fbc548ca33dd2a39f4667003
13. Matera MG, **Ora J**, Calzetta L, Rogliani P, Cazzola M. Investigational anti IL-13 asthma treatments: a 2023 update. Expert Opinion on Investigational Drugs [Internet]. 2023;32(5):373–86. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159683701&doi=10.1080%2f13543784.2023.2215425&partnerID=40&md5=d2c2b445a4d1a04485ff7c7496ebbe84
14. Matera MG, Calzetta L, Cazzola M, **Ora J**, Rogliani P. Biologic therapies for chronic obstructive pulmonary disease. Expert Opinion on Biological Therapy [Internet]. 2023;23(2):163–73. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85145289365&doi=10.1080%2f14712598.2022.2160238&partnerID=40&md5=e2c5df68ccf314458d68e10f3fae62e1
15. Manzetti GM, **Ora J**, Sepiacci A, Cazzola M, Rogliani P, Calzetta L. Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement. International Journal of COPD [Internet]. 2023;18:2225–43. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174464931&doi=10.2147%2fCOPD.S396945&partnerID=40&md5=17587069297661f235ec5afd5283960c
16. Cazzola M, Rogliani P, **Ora J**, Calzetta L, Lauro D, Matera MG. Hyperglycaemia and Chronic Obstructive Pulmonary Disease. Diagnostics [Internet]. 2023;13(21). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85176389020&doi=10.3390%2fdiagnostics13213362&partnerID=40&md5=63f103e0b250067719b15b4e814f8c14
17. Cazzola M, Rogliani P, **Ora J,** Calzetta L, Matera MG. Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences. Therapeutic Advances in Chronic Disease [Internet]. 2023;14. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85161300481&doi=10.1177%2f20406223231171556&partnerID=40&md5=94ba27c49de5b5ce6b5152aef6809589
18. Calzetta L, Chetta A, Aiello M, Frizzelli A, **Ora J**, Melis E, et al. The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma. Vaccines [Internet]. 2023;11(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149208019&doi=10.3390%2fvaccines11020282&partnerID=40&md5=18a782d3275388fcd664147e8aec2529
19. Rogliani P, Ritondo BL, Cavalli F, Giorgino FM, Girolami A, Pane G, et al. Synergy across the drugs approved for the treatment of asthma. Minerva Medica [Internet]. 2022;113(1):17–30. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128330405&doi=10.23736%2fS0026-4806.21.07266-9&partnerID=40&md5=13e5ccffa2b5cddbd4f6c97067d5210c
20. Rogliani P, **Ora J,** Cavalli F, Cazzola M, Calzetta L. Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score. Journal of Clinical Medicine [Internet]. 2022;11(15). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-

85136917141&doi=10.3390%2fjcm11154491&partnerID=40&md5=655a58c84ba6703bee3871116dc108dd

21. Rogliani P, **Ora J,** Calzetta L, Matera MG, Cazzola M. Asthma and comorbidities: recent advances. Polish Archives of Internal Medicine [Internet]. 2022;132(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129643232&doi=10.20452%2fpamw.16250&partnerID=40&md5=bf2d5f0a766b4258ec0266976f2617df
22. **Ora J,** Zerillo B, De Marco P, Manzetti GM, De Guido I, Calzetta L, et al. Effects of SARS-CoV-2 Infection on Pulmonary Function Tests and Exercise Tolerance. Journal of Clinical Medicine [Internet]. 2022;11(17). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137766848&doi=10.3390%2fjcm11174936&partnerID=40&md5=f8fcb1d80d2b40e4b9c06c3fa2defe92
23. **Ora J,** Prendi E, Ritondo BL, Pata X, Spada F, Rogliani P. Pulmonary Rehabilitation in Noncystic Fibrosis Bronchiectasis. Respiration [Internet]. 2022;101(1):97–105. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112381358&doi=10.1159%2f000517527&partnerID=40&md5=7e426c7081c59055070d73e8a2738bb6
24. **Ora J**, Prendi E, Attinà ML, Cazzola M, Calzetta L, Rogliani P. Efficacy of respiratory tele-rehabilitation in COPD patients: Systematic review and meta-analysis. Monaldi Archives for Chest Disease [Internet]. 2022;92(4). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137091998&doi=10.4081%2fmonaldi.2022.2105&partnerID=40&md5=3b08ca815f0859e4f41e42725d5a504a
25. **Ora J**, Coppola A, Perduno A, Manzetti GM, Puxeddu E, Rogliani P. Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. Monaldi Archives for Chest Disease [Internet]. 2022;92(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85129779537&doi=10.4081%2fmonaldi.2021.1925&partnerID=40&md5=c72e3084693506019069d94e4856e1f0
26. Cazzola M, Rogliani P, Calzetta L, **Ora J**, Matera MG. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology [Internet]. 2022;15(3):269–83. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130272041&doi=10.1080%2f17512433.2022.2071700&partnerID=40&md5=65c182d074a994682e4cdd0f5538ae4a
27. Cazzola M, **Ora J**, Calzetta L, Rogliani P, Matera MG. The future of inhalation therapy in chronic obstructive pulmonary disease. Current Research in Pharmacology and Drug Discovery [Internet]. 2022;3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85124739798&doi=10.1016%2fj.crphar.2022.100092&partnerID=40&md5=f5d15fef10f2fe6ea2f29936f7fb87e3
28. Cazzola M, **Ora J**, Calzetta L, Rogliani P, Matera MG. Advances in inhaled corticosteroids for the treatment of chronic obstructive pulmonary disease: what is their value today? Expert Opinion on Pharmacotherapy [Internet]. 2022;23(8):917–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130921919&doi=10.1080%2f14656566.2022.2076592&partnerID=40&md5=8136fe2b8966f9465ac654eab4ee48fc
29. Rogliani P, **Ora J**, Girolami A, Rossi I, de Guido I, Facciolo F, et al. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study. Pulmonary Pharmacology and Therapeutics [Internet]. 2021;69. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109105394&doi=10.1016%2fj.pupt.2021.102050&partnerID=40&md5=889c170f99487984c68d338a4d51bd5e
30. **Ora J**, Rogliani P, Dauri M, O'Donnell D. Happy hypoxemia, or blunted ventilation? Respiratory Research [Internet]. 2021;22(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098800159&doi=10.1186%2fs12931-020-01604-9&partnerID=40&md5=ae5de1406d7350ba40457f35fb5024e3

31. **Ora J,** Calzetta L, Ritondo BL, Matera MG, Rogliani P. Current long-acting muscarinic antagonists for the treatment of asthma. Expert Opinion on Pharmacotherapy [Internet]. 2021;22(17):2343–57. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110930953&doi=10.1080%2f14656566.2021.1952182&partnerID=40&md5=68fb7d06d4360844cd3401d043dda82d
32. Matera MG, **Ora J**, Cavalli F, Rogliani P, Cazzola M. New avenues for phosphodiesterase inhibitors in asthma. Journal of Experimental Pharmacology [Internet]. 2021;13:291–302. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103285360&doi=10.2147%2fJEP.S242961&partnerID=40&md5=6067f209ef8f912280cce893f0926bcf
33. Matera MG, **Ora J**, Calzetta L, Rogliani P, Cazzola M. Sex differences in COPD management. Expert Review of Clinical Pharmacology [Internet]. 2021;14(3):323–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102566770&doi=10.1080%2f17512433.2021.1888713&partnerID=40&md5=7c7e2e0b4678247dc52dd28eeb77b366
34. Matera MG, Calzetta L, **Ora J**, Rogliani P, Cazzola M. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opinion on Drug Delivery [Internet]. 2021;18(7):891–906. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85099648656&doi=10.1080%2f17425247.2021.1873271&partnerID=40&md5=0f7a3f0b337af2c86e69418950d5d50f
35. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders [Internet]. 2021;278:339–40. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091570041&doi=10.1016%2fj.jad.2020.09.042&partnerID=40&md5=05cf1ef42435ab5bc545ea50e5e69f76
36. Cazzola M, Rogliani P, Salvi SS, **Ora J**, Matera MG. Use of Thiols in the Treatment of COVID-19: Current Evidence. Lung [Internet]. 2021;199(4):335–43. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85113689457&doi=10.1007%2fs00408-021-00465-3&partnerID=40&md5=e68a3ca8c2f13545f6a75ec946fd067b
37. Cazzola M, **Ora J**, Cavalli F, Rogliani P, Matera MG. Treatable Mechanisms in Asthma. Molecular Diagnosis and Therapy [Internet]. 2021;25(2):111–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100812273&doi=10.1007%2fs40291-021-00514-w&partnerID=40&md5=8169cf520e42ac353e270bc1f5997bb3
38. Cazzola M, **Ora J**, Cavalli F, Rogliani P, Matera MG. An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biologics: Targets and Therapy [Internet]. 2021;15:363–74. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114174421&doi=10.2147%2fBTT.S295409&partnerID=40&md5=ba1ae1297155b201ed6106bc12dde4d1
39. Cazzola M, **Ora J**, Bianco A, Rogliani P, Matera MG. Management of COPD patients during COVID: difficulties and experiences. Expert Review of Respiratory Medicine [Internet]. 2021;15(8):1025–33. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106243600&doi=10.1080%2f17476348.2021.1929176&partnerID=40&md5=d4634287d83e0c6bbfab02ff1181dcfd
40. Cazzola M, **Ora J**, Bianco A, Rogliani P, Matera MG. Guidance on nebulization during the current COVID-19 pandemic. Respiratory Medicine [Internet]. 2021;176. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098471988&doi=10.1016%2fj.rmed.2020.106236&partnerID=40&md5=9bdd7ecbb1a6b811a8e6f9957f99b187
41. Cazzola M, Matera MG, Rogliani P, Calzetta L, **Ora J**. Step-up and step-down approaches in the treatment of asthma. Expert Review of Respiratory Medicine [Internet]. 2021;15(9):1159–68. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85107463830&doi=10.1080%2f17476348.2021.1935245&partnerID=40&md5=1de92dcb208b285e581aec0888a60236
42. Rogliani P, Ritondo BL, **Ora J**, Cazzola M, Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. European Respiratory Journal [Internet]. 2020;56(3). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-

85089602797&doi=10.1183%2f13993003.00625-2020&partnerID=40&md5=e29f6c5cc1e03b8ba35ca0c86845bef8

43. Paone G, De Rose G, **Ora J**. Basic key aspects of physiology of idiopathic pulmonary fibrosis. In: Respiratory Ventilatory Strategies in Acute and Chronic Respiratory Failure in Idiopathic Pulmonary Diseases: A Practical Approach [Internet]. 2020. p. 17–25. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85144562159&partnerID=40&md5=d037c0b935bc117eda8ec4c31d07fa82
44. **Ora J**, Puxeddu E, Cavalli F, Giorgino FM, Girolami A, Chiocchi M, et al. Does bronchoscopy help the diagnosis in COVID-19 infection? European Respiratory Journal [Internet]. 2020;56(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089302124&doi=10.1183%2f13993003.01619-2020&partnerID=40&md5=7cb67bfa4279f023d2ed98deb9fe0faa
45. **Ora J**, Liguori C, Puxeddu E, Coppola A, Matino M, Pierantozzi M, et al. Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. Neurological Sciences [Internet]. 2020;41(10):2671–4. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088818432&doi=10.1007%2fs10072-020-04632-x&partnerID=40&md5=8558b755d9c26569a26ad2b67b438d0a
46. **Ora J**, Coppola A, Cazzola M, Calzetta L, Rogliani P. Long-acting muscarinic antagonists under investigational to treat chronic obstructive pulmonary disease. Journal of Experimental Pharmacology [Internet]. 2020;12:559–74. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85098112865&doi=10.2147%2fJEP.S259330&partnerID=40&md5=28dd5a15ecc7ea347456ce571af0aade
47. **Ora J**, Cavalli F, Cazzola M. Management of patients with asthma or COPD and cardiovascular disease: Risks versus benefits. ERS Monograph [Internet]. 2020;2020(9781849841191):66–81. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089710460&doi=10.1183%2f2312508X.10027419&partnerID=40&md5=321d6611e9a8542d78ca97ffb6b17e32
48. **Ora J**, Calzetta L, Matera MG, Cazzola M, Rogliani P. Advances with glucocorticoids in the treatment of asthma: state of the art. Expert Opinion on Pharmacotherapy [Internet]. 2020;21(18):2305–16. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089558076&doi=10.1080%2f14656566.2020.1807514&partnerID=40&md5=f4a941f56ccb8dbac0c666394146d29f
49. Liguori C, Pierantozzi M, Spanetta M, Sarmati L, Cesta N, Iannetta M, et al. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity [Internet]. 2020;88:11–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085771174&doi=10.1016%2fj.bbi.2020.05.037&partnerID=40&md5=38bc23127ef0892d2222540a2b1e9b2d
50. Rogliani P, Calzetta L, **Ora J**, Cazzola M, Matera MG. Efficacy and safety profile of doxofylline compared to theophylline in asthma: A meta-analysis. Multidisciplinary Respiratory Medicine [Internet]. 2019;14(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070218455&doi=10.1186%2fs40248-019-0189-0&partnerID=40&md5=fdbd4641f34f2310a8c474853a0bc03c
51. Rogliani P, Calzetta L, Matera MG, di Daniele N, Girolami A, Cazzola M, et al. Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy [Internet]. 2019;20(6):737–50. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063431177&doi=10.1080%2f14656566.2019.1570133&partnerID=40&md5=9f57176d9451065b531d5bc81a62409d
52. Cazzola M, Puxeddu E, **Ora J**, Rogliani P. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Molecular Diagnosis and Therapy [Internet]. 2019;23(5):603–14. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069935670&doi=10.1007%2fs40291-019-00413-1&partnerID=40&md5=876ac90edbcda1c0f54ab82d87a4ea74
53. Rogliani P, **Ora J**, Puxeddu E, Calzetta L, Cavalli F, Matera MG, et al. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics [Internet]. 2018;49:20–6. Available from:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85042795988&doi=10.1016%2fj.pupt.2017.12.010&partnerID=40&md5=dabb5068af8738da1f2569fe300c1bf8

54. Rogliani P, **Ora J**, Matera MG, Cazzola M, Calzetta L. The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety [Internet]. 2018;17(6):589–96. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85048307129&doi=10.1080%2f14740338.2018.1472232&partnerID=40&md5=c5dac55c78e9ef95f8b3bb5f059b8a84
55. Rogliani P, **Ora J**, Di Daniele N, Lauro D. Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD. Current Opinion in Pharmacology [Internet]. 2018;40:34–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041425270&doi=10.1016%2fj.coph.2018.01.002&partnerID=40&md5=df58e9fcefa75ab39b97717f8c152aa8
56. Matera MG, Rogliani P, **Ora J**, Cazzola M. Current pharmacotherapeutic options for pediatric lower respiratory tract infections with a focus on antimicrobial agents. Expert Opinion on Pharmacotherapy [Internet]. 2018;19(18):2043–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058565438&doi=10.1080%2f14656566.2018.1534957&partnerID=40&md5=24b1f03c26b0af886cdf0b3b475d726f
57. Faverio P, De Giacomi F, Sardella L, Fiorentino G, Carone M, Salerno F, et al. Management of acute respiratory failure in interstitial lung diseases: Overview and clinical insights. BMC Pulmonary Medicine [Internet]. 2018;18(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85047068745&doi=10.1186%2fs12890-018-0643-3&partnerID=40&md5=59c88d20b8abd559dc69cd9f4f8bd0d7
58. Cazzola M, Rogliani P, Puxeddu E, **Ora J**, Matera MG. An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? Expert Review of Respiratory Medicine [Internet]. 2018;12(1):43–54. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038232673&doi=10.1080%2f17476348.2018.1398086&partnerID=40&md5=a501258ce3fa96c87121c90048341897
59. Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, et al. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: An international case-cohort study. European Respiratory Journal [Internet]. 2017;50(2). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023612291&doi=10.1183%2f13993003.00936-2017&partnerID=40&md5=68d646aa8e6cc212c3387071f1c94732
60. Rogliani P, **Ora J**, Puxeddu E, Matera MG, Cazzola M. Adherence to COPD treatment: Myth and reality. Respiratory Medicine [Internet]. 2017;129:117–23. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021091111&doi=10.1016%2fj.rmed.2017.06.007&partnerID=40&md5=0b6da4e52b1711e97fe25e4463282786
61. Rogliani P, Matera MG, **Ora J**, Cazzola M, Calzetta L. The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: A quantitative synthesis. International Journal of COPD [Internet]. 2017;12:3469–85. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85037732675&doi=10.2147%2fCOPD.S146338&partnerID=40&md5=0b780b942517f53eee95218478e7e665
62. Rogliani P, Calzetta L, Coppola A, Cavalli F, **Ora J**, Puxeddu E, et al. Optimizing drug delivery in COPD: The role of inhaler devices. Respiratory Medicine [Internet]. 2017;124:6–14. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010280751&doi=10.1016%2fj.rmed.2017.01.006&partnerID=40&md5=0cade940eff45b281f69b58b0e229424
63. Cazzola M, **Ora J**, Rogliani P, Matera MG. Role of muscarinic antagonists in asthma therapy. Expert Review of Respiratory Medicine [Internet]. 2017;11(3):239–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013820746&doi=10.1080%2f17476348.2017.1289844&partnerID=40&md5=01c84aad8408eda24f74d138abd224bf

64. Cazzola M, **Ora J**, Puxeddu E, Rogliani P. Indacaterol/Glycopyrronium Combination for COPD. Pulmonary Therapy [Internet]. 2017;3(1):45–57. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032734287&doi=10.1007%2fs41030-016-0024-0&partnerID=40&md5=21fc2b3daab3b0a861f2a545d2b7bc00
65. Calzetta L, Rogliani P, **Ora J**, Puxeddu E, Cazzola M, Matera MG. LABA/LAMA combination in copd: A meta-analysis on the duration of treatment. European Respiratory Review [Internet]. 2017;26(143). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010289798&doi=10.1183%2f16000617.0043-2016&partnerID=40&md5=ff5403697114f3d70f5a535355276348
66. Calzetta L, **Ora J**, Cavalli F, Rogliani P, O'Donnell DE, Cazzola M. Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respiratory Medicine [Internet]. 2017;129:189–98. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021646271&doi=10.1016%2fj.rmed.2017.06.020&partnerID=40&md5=cb32cf27d43fd39598e6b93377055626
67. Braido F, Baiardini I, Alleri P, Bacci E, Barbetta C, Bellocchia M, et al. Asthma management in a specialist setting: Results of an Italian Respiratory Society survey. Pulmonary Pharmacology and Therapeutics [Internet]. 2017;44:83–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016325173&doi=10.1016%2fj.pupt.2017.03.013&partnerID=40&md5=7763458663fa5e9ead5908a1e19ca17d
68. Salvati A, **Ora J**, Donatucci B, Rogliani P. Cardiopulmonary exercise test in athletes and coronary diseases. Medicina dello Sport [Internet]. 2016;69(2):289–96. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84992476758&partnerID=40&md5=73c3fae7cff2d155050e9b9b5ab79770
69. Rogliani P, Puxeddu E, Ciaprini C, **Ora J**, Onorato A, Pezzuto G, et al. The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils. BioMed Research International [Internet]. 2016;2016. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994641724&doi=10.1155%2f2016%2f4547953&partnerID=40&md5=2e5ac7b9860c8d1ba00a1fb61ac1088e
70. Rogliani P, **Ora J**, Puxeddu E, Cazzola M. Airflow obstruction: Is it asthma or is it COPD? International Journal of COPD [Internet]. 2016;11(1):3007–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007490506&doi=10.2147%2fCOPD.S54927&partnerID=40&md5=a50411e4e1976ad4fc45079d8c3eaac1
71. Liccardi G, Salzillo A, Calzetta L, **Ora J**, Rogliani P. Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link? Respirology [Internet]. 2016;21(8):1496–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991490860&doi=10.1111%2fresp.12896&partnerID=40&md5=fc9eda530c719c5c07405513796d8110
72. Liccardi G, Salzillo A, Calzetta L, **Ora J**, Rogliani P. Dog allergen immunotherapy and allergy to furry animals. Annals of Allergy, Asthma and Immunology [Internet]. 2016;116(6):590. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84971673298&doi=10.1016%2fj.anai.2016.04.007&partnerID=40&md5=35e1cd04f83163099b1e81ceb8946775
73. Liccardi G, Salzillo A, Calzetta L, **Ora J**, Cazzola M, Matera MG, et al. Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? Journal of Allergy and Clinical Immunology: In Practice [Internet]. 2016;4(4):791–3. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018669250&doi=10.1016%2fj.jaip.2016.03.025&partnerID=40&md5=e3558f67661a383e30002c514d671663
74. Faisal A, Alghamdi BJ, Ciavaglia CE, Elbehairy AF, Webb KA, **Ora J**, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. American Journal of Respiratory and Critical Care Medicine [Internet]. 2016;193(3):299–309. Available from:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961190233&doi=10.1164%2frccm.201504-0841OC&partnerID=40&md5=cf9db730ee05c59af73e4a6b911df6a0

75. Cazzola M, Rogliani P, **Ora J**, Matera MG. Treatment options for moderate-to-very severe chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy [Internet]. 2016;17(7):977–88. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84961393014&doi=10.1517%2f14656566.2016.1155555&partnerID=40&md5=d71525ff72e92b0d61c1fe1f318607d9
76. Cazzola M, Rinaldi B, Lucà G, **Ora J**. Olodaterol for the treatment of asthma. Expert Opinion on Investigational Drugs [Internet]. 2016;25(7):861–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969850223&doi=10.1080%2f13543784.2016.1188078&partnerID=40&md5=117551238d1b794474bea7e959987857
77. Cazzola M, **Ora J**, Puxeddu E. Dual bronchodilation and exacerbations of COPD. Journal of Thoracic Disease [Internet]. 2016;8(9):2383–6. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991217836&doi=10.21037%2fjtd.2016.08.92&partnerID=40&md5=43bb6122006d40836d35558d0268140a
78. Cazzola M, **Ora J**, Di Paolo A, Puxeddu E, Calzetta L, Rogliani P. Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. Pulmonary Pharmacology and Therapeutics [Internet]. 2016;39:48–53. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84976359294&doi=10.1016%2fj.pupt.2016.06.006&partnerID=40&md5=976fdc5541f2a52870b2d4c0026227b9
79. Cazzola M, Calzetta L, Puxeddu E, **Ora J**, Facciolo F, Rogliani P, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respiratory Research [Internet]. 2016;17(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84973623311&doi=10.1186%2fs12931-016-0386-8&partnerID=40&md5=8019fba0502d3ea2f2e64e757d9f0030
80. Rogliani P, Calzetta L, **Ora J**, Lipsi R, Segreti A, Matera MG, et al. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology [Internet]. 2015;761:383–90. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938950539&doi=10.1016%2fj.ejphar.2015.04.042&partnerID=40&md5=af6813713bd6ea417ffd0cfc0b19f498
81. Rogliani P, Calzetta L, **Ora J**, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics [Internet]. 2015;31:15–27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926285094&doi=10.1016%2fj.pupt.2015.01.005&partnerID=40&md5=38fe6d2bc73c4ebfffe960baafba5432
82. Matera MG, **Ora J**, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – Focus on olodaterol. Therapeutics and Clinical Risk Management [Internet]. 2015;11:1805–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949756566&doi=10.2147%2fTCRM.S73581&partnerID=40&md5=512f6d8510c5bb9fc1931d805229baa0
83. Cazzola M, Segreti A, Capuano R, Bergamini A, Martinelli E, Calzetta L, et al. Analysis of exhaled breath fingerprints and volatile organic compounds in COPD. COPD Research and Practice [Internet]. 2015;1(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85002446906&doi=10.1186%2fs40749-015-0010-1&partnerID=40&md5=eb5b6eac0ae8ded38b74e72d2023659b
84. Cazzola M, Rogliani P, **Ora J**, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology [Internet]. 2015;8(5):529–39. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939784979&doi=10.1586%2f17512433.2015.1075389&partnerID=40&md5=a9446c202efe68e88a0e6b6a58ee7019

85. Cazzola M, Calzetta L, **Ora J**, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. Respiratory Medicine [Internet]. 2015;109(10):1305–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942885527&doi=10.1016%2fj.rmed.2015.08.005&partnerID=40&md5=d74aeada2b130ac5c24f5f0c67aa14bb
86. Rogliani P, **Ora J**, Ciaprini C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respiratory Medicine [Internet]. 2014;108(2):307–13. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893724878&doi=10.1016%2fj.rmed.2013.10.022&partnerID=40&md5=84889a0acd15a0b2b25c0eaf8337477f
87. Ciavaglia CE, Guenette JA, **Ora J**, Webb KA, Neder JA, O'Donnell DE. Does exercise test modality influence dyspnoea perception in obese patients with COPD? European Respiratory Journal [Internet]. 2014;43(6):1621–30. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901847720&doi=10.1183%2f09031936.00151513&partnerID=40&md5=76dff6c210a9eaaa4a36d3f072f98aea
88. **Ora J**, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, et al. A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respiratory Medicine [Internet]. 2013;107(12):2014–21. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890312181&doi=10.1016%2fj.rmed.2013.10.002&partnerID=40&md5=4ed142f32d59c4133ea885f7a3961bfa
89. Fiorentini A, **Ora J**, Tubani L. Autonomic system modification in zen practitioners. Indian Journal of Medical Sciences [Internet]. 2013;67(7–8):161–7. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893872404&doi=10.4103%2f0019-5359.125877&partnerID=40&md5=08a7e21e7f802caee6f35ad17d99fb02
90. Cazzola M, Segreti A, Stirpe E, Puxeddu E, **Ora J**, Rogliani P, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respiratory Medicine [Internet]. 2013;107(1):107–11. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871358712&doi=10.1016%2fj.rmed.2012.09.022&partnerID=40&md5=56e42b4e3eddcdd02b48586fc6c6659e
91. Lougheed MD, **Ora J**, O'Donnell DE. Long-Acting Muscarinic Antagonists in Asthma and COPD. In: Advances in Combination Therapy for Asthma and COPD [Internet]. 2012. p. 268–95. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886165950&doi=10.1002%2f9781119998624.ch11&partnerID=40&md5=8d4a4b31f6666d86a8c96d6cee3da3e5
92. **Ora J**, Laveneziana P, Wadell K, Preston M, Webb KA, O'Donnell DE. Effect of obesity on respiratory mechanics during rest and exercise in COPD. Journal of Applied Physiology [Internet]. 2011;111(1):10–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960276266&doi=10.1152%2fjapplphysiol.01131.2010&partnerID=40&md5=ea6dc17321dfaf2574a3bd85c49713a1
93. Laveneziana P, Webb KA, **Ora J**, Wadell K, O'Donnell DE. Evolution of dyspnea during exercise in chronic obstructive pulmonary disease impact of critical volume constraints. American Journal of Respiratory and Critical Care Medicine [Internet]. 2011;184(12):1367–73. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84455201660&doi=10.1164%2frccm.201106-1128OC&partnerID=40&md5=3c80290ed7bfdf7eedf11d9f8226493f
94. Aliverti A, Kayser B, Mauro ALO, Quaranta M, Pompilio P, Dellacà RL, et al. Respiratory and leg muscles perceived exertion during exercise at altitude. Respiratory Physiology and Neurobiology [Internet]. 2011;177(2):162–8. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957517119&doi=10.1016%2fj.resp.2011.03.014&partnerID=40&md5=f55d88f80717156dd45bb3a2a6510102
95. **Ora J**, O'Donnell DE. Modern management of chronic obstructive pulmonary disease. Minerva Pneumologica [Internet]. 2010;49(1):1–16. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77953585631&partnerID=40&md5=1cfe09c3e68038a03538def55a1d8874
96. **Ora J**, Jensen D, O'Donnell DE. Exertional dyspnea in chronic obstructive pulmonary disease: Mechanisms and treatment approaches. Current Opinion in Pulmonary Medicine [Internet].

2010;16(2):144–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-76449091139&doi=10.1097%2fMCP.0b013e328334a728&partnerID=40&md5=5a7b4788da7f06105c485c18700ad554

97. O'Donnell DE, **Ora J**, Laveneziana P. Clinical benefits of maximal bronchodilation in chronic obstructive pulmonary disease (Part I). Hot Topics in Respiratory Medicine [Internet]. 2010;(12):25–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-79957469879&partnerID=40&md5=4f75f46d9868d61f568af219dbd44712
98. Deesomchok A, Fisher T, Webb KA, **Ora J**, Lam YM, Lougheed MD, et al. Effects of obesity on perceptual and mechanical responses to bronchoconstriction in asthma. American Journal of Respiratory and Critical Care Medicine [Internet]. 2010;181(2):125–33. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-74949131555&doi=10.1164%2frccm.200906-0934OC&partnerID=40&md5=9459724c21f80193cced174fe9fc2491
99. **Ora J**, Laveneziana P, Ofir D, Deesomchok A, Webb KA, O'Donnell DE. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. American Journal of Respiratory and Critical Care Medicine [Internet]. 2009;180(10):964–71. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-72849133815&doi=10.1164%2frccm.200904-0530OC&partnerID=40&md5=6159af71104d5bb968c59e4d5bc0dce8
100. O'Donnell DE, **Ora J**, Webb KA, Laveneziana P, Jensen D. Mechanisms of activity-related dyspnea in pulmonary diseases. Respiratory Physiology and Neurobiology [Internet]. 2009;167(1):116–32. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-67349130812&doi=10.1016%2fj.resp.2009.01.010&partnerID=40&md5=b69cedcc2fe1932aa4cfc075fb6ecc3e
101. O'Donnell DE, Laveneziana P, **Ora J**, Webb KA, Lam YM, Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage i COPD. Thorax [Internet]. 2009;64(3):216–23. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-61649088166&doi=10.1136%2fthx.2008.103598&partnerID=40&md5=eb05ca278add2d72a3235ef88a5c80c3
102. Laveneziana P, Palange P, **Ora J**, Martolini D, O'Donnell DE. Bronchodilator effect on ventilatory, pulmonary gas exchange, and heart rate kinetics during high-intensity exercise in COPD. European Journal of Applied Physiology [Internet]. 2009;107(6):633–43. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-76649126384&doi=10.1007%2fs00421-009-1169-4&partnerID=40&md5=69cb6aa9e6dc2b5f0ed995a5112d1958
103. Onorati P, Martolini D, **Ora J**, Valli G, Fedeli A, Palange P. Estimation of the exercise ventilatory compensation point by the analysis of the relationship between minute ventilation and heart rate. European Journal of Applied Physiology [Internet]. 2008;104(1):87–94. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-46749083342&doi=10.1007%2fs00421-008-0777-8&partnerID=40&md5=a7122fbb35ae91f435795df7914c5c2f
104. Perciaccante A, Fiorentini A, **Ora J**, Paris A, Serra P. A case of pancytopenia and splenomegaly: Haematological disease? [6]. Internal and Emergency Medicine [Internet]. 2007;2(3):238–42. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-35948946445&doi=10.1007%2fs11739-007-0069-z&partnerID=40&md5=a10f3c4711dbef93a56e2c8fad3d36f4

ULTERIORI INFORMAZIONI

- **Affiliazioni**
  - Membro ERS (European Respiratory Society) dal 2009
  - Membro AIPO (Associazione Italiana di Pneumologia Ospedaliera) dal 2015 (ruolo nel Consiglio Esecutivo Regionale Lazio e coordinamento macroarea Fisiopatologia Respiratoria)
- **Abilitazione professionale**
  - Iscrizione all'Ordine dei Medici di Roma (n. 52902, dal 09/12/2003)

DICHIARAZIONI FINALI

Il sottoscritto, consapevole delle sanzioni previste dagli artt. 75 e 76 del D.P.R. n. 445/2000 per dichiarazioni mendaci, **dichiara** che le informazioni sopra riportate sono veritiere.

Data: 16/01/2026 **Firma**: